# Sentinel node in ovarian cancer

Published: 05-09-2012 Last updated: 30-04-2024

Primary Objective: - Determine whether or not a sentinel node procedure in patients with ovarian cancer is feasible. Secondary Objective(s): - The anatomical location(s) of the sentinel

node(s).- Incidence of false negative nodes.

**Ethical review** Approved WMO **Status** Recruitment stopped

**Health condition type** Reproductive neoplasms female malignant and unspecified

**Study type** Observational invasive

## **Summary**

#### ID

NL-OMON37538

**Source** 

ToetsingOnline

**Brief title**SONAR study

#### **Condition**

• Reproductive neoplasms female malignant and unspecified

#### **Synonym**

malignancy of the ovary, ovarian cancer

### Research involving

Human

## Sponsors and support

**Primary sponsor:** Medisch Universitair Ziekenhuis Maastricht

Source(s) of monetary or material Support: Ministerie van OC&W

#### Intervention

**Keyword:** Cancer, Node, Ovarian, Sentinel

### **Outcome measures**

#### **Primary outcome**

Percentage of patients in whom sentinel node(s) will be identified.

### **Secondary outcome**

- Location of the sentinel node(s)
- Incidence of false negative nodes.

# **Study description**

### **Background summary**

As most cancers, ovarian cancer also spreads to regional lymph nodes. The sentinel lymph node is hypothetical the first lymph node or group of nodes draining a cancer. If the sentinel node(s) does not contain cancer, there is a high likelihood that the cancer has not spread to other lymph nodes. This means that, at least theoretically, a radical lymphadenectomy or extensive lymph node sampling could be omitted and thus the associated morbidity. The sentinel node technique was proven to be effective in other cancers such as breast cancer and malignant melanoma, and in the gynaecological field in vulvar cancer. Currently sentinel node studies are done for cervix en uterine cancer.

### Study objective

#### Primary Objective:

- Determine whether or not a sentinel node procedure in patients with ovarian cancer is feasible.

#### Secondary Objective(s):

- The anatomical location(s) of the sentinel node(s).
- Incidence of false negative nodes.

#### Study design

Phase I: feasibility study to detect sentinel nodes: mapping the lymphatic drainage of the ovaries.

## Study burden and risks

The surgery is prolonged with 20-25 minutes due to the required incubation time after injection of the blue dye and radioactive isotope. A scintigram will be performed the day after the surgery to determine whether residual radioactive lymph nodes can be detected. The scintigram will only be performed if the patient is capable to be transported to the nuclear department. No extra blood samples will be taken, no extra visits, physical examinations or other tests are necessary. There is a 0.9% risk of an allergic reaction to the blue dye of which 0.07% severe (anaphylactic shock). The dose of radioactive isotope given does not give adverse side effects, either to the patients or the personnel present in the operating theatre.

## **Contacts**

#### **Public**

Medisch Universitair Ziekenhuis Maastricht

P. Debyelaan 25 Maastricht 6229HX NL

#### **Scientific**

Medisch Universitair Ziekenhuis Maastricht

P. Debyelaan 25 Maastricht 6229HX NL

## **Trial sites**

### **Listed location countries**

**Netherlands** 

# **Eligibility criteria**

#### Age

Adults (18-64 years) Elderly (65 years and older)

### Inclusion criteria

The following patients will be included:

Cohort 1: patients with a high suspicion of an ovarian malignancy in whom a median laparotomy and a frozen section analysis is planned.

Cohort 2: patients with endometrial cancer in whom a staging laparotomy is planned.

### **Exclusion criteria**

- Previous surgery of the ovaries.
- Previous vascular surgery of the aorta, caval vein, and/or iliac vessels
- Previous lymphadenectomy of lymph node sampling in the iliac or para-aortal region.
- History of a malignant lymphoma
- History of a malignant tumour in the abdominal cavity.
- Previous allergic reaction to blue dye.
- Pregnant or lactating patients

## Study design

## **Design**

Study type: Observational invasive

Masking: Open (masking not used)

Control: Uncontrolled

Primary purpose: Diagnostic

### Recruitment

NL

Recruitment status: Recruitment stopped

Start date (anticipated): 10-10-2012

Enrollment: 28

Type: Actual

# **Ethics review**

Approved WMO

Date: 05-09-2012

Application type: First submission

Review commission: METC academisch ziekenhuis Maastricht/Universiteit

Maastricht, METC azM/UM (Maastricht)

Approved WMO

Date: 25-07-2013
Application type: Amendment

Review commission: METC academisch ziekenhuis Maastricht/Universiteit

Maastricht, METC azM/UM (Maastricht)

# **Study registrations**

## Followed up by the following (possibly more current) registration

No registrations found.

## Other (possibly less up-to-date) registrations in this register

No registrations found.

## In other registers

Register ID

CCMO NL40323.068.12